Maurice Swanson, Ph.D., Professor of Molecular Genetics and Microbiology at University of Florida, Gainesville, and a team of researchers have found that the muscleblind-like 2 (MBNL2) protein in the central nervous system (CNS) may be responsible for the neurological impacts of myotonic dystrophy
We recently talked about the development of Stanford's new Center for DM Care and Research with Dr. John Day, Professor of Neurology and & Neurological Sciences and Director of the Division of Neuromuscular Medicine and Neuromuscular Clinics at Stanford University.
MENLO PARK, CA (February 28, 2013) The Myotonic Dystrophy Foundation (MDF) announced today that it has launched the Myotonic Dystrophy Family Registry (MDFR), a new online database designed to help both individuals living with myotonic dystrophy (DM), and the researchers and medical professionals studying the rare disease.
On Rare Disease Day 2013 -- February 28th -- you'll be able to take a more active role in the fight against myotonic dystrophy (DM) by joining the new Myotonic Dystrophy Family Registry (MDFR).
Methylphenidate, a psycho-stimulant drug, also known by its 1948 trademarked name of Ritalin, could be useful in the treatment of excessive daytime sleepiness (EDS) for DM1 patients, according to a recent study conducted by The Department of Human Genetics at the Centre Hospitalier Universitaire de Quebec in Quebec City, Canada.